Gaudium IVF and Women Health Limited announced its audited financial results for the quarter and year ended March 31, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance - Q4FY26 vs Q4FY25

  • Revenue from Operations: ₹30.35 Cr (vs ₹26.92 Cr), growth of 12.74% YoY
  • EBITDA: ₹12.17 Cr (vs ₹8.72 Cr), growth of 39.56% YoY
  • EBITDA Margin: 40.10% (vs 32.39%), improvement of 771 bps
  • Profit After Tax (from continuing operations): ₹8.36 Cr (vs ₹6.45 Cr), growth of 29.46% YoY
  • PAT Margin: 27.54% (vs 23.98%), improvement of 356 bps

Financial Performance - Q4FY26 vs Q3FY26

  • Revenue from Operations: ₹30.35 Cr (vs ₹24.50 Cr), growth of 23.85% QoQ
  • EBITDA: ₹12.17 Cr (vs ₹6.55 Cr), growth of 85.81% QoQ
  • EBITDA Margin: 40.10% (vs 26.73%), improvement of 1337 bps
  • Profit After Tax: ₹8.36 Cr (vs ₹3.63 Cr), growth of 130.20% QoQ
  • PAT Margin: 27.54% (vs 14.81%), improvement of 1273 bps

Financial Performance - FY26 vs FY25

  • Revenue from Operations: ₹104.35 Cr (vs ₹70.72 Cr), growth of 47.56% YoY
  • EBITDA: ₹37.70 Cr (vs ₹28.63 Cr), growth of 31.69% YoY
  • EBITDA Margin: 36.13% (vs 40.48%), decline of 435 bps
  • Profit After Tax: ₹24.48 Cr (vs ₹19.17 Cr), growth of 27.69% YoY
  • PAT Margin: 23.47% (vs 27.12%), decline of 365 bps

Operational Highlights

  • Maintained network of 7 hubs and 28 spokes in FY26
  • Achieved clinical pregnancy success rate of 58% on first IVF attempt
  • Growth driven by higher patient volume at mature hubs and high clinical success rate
  • EBITDA margin supported by operating leverage and richer mix of advanced IVF protocols

Strategic Developments

  • In April 2026, became first IVF chain in India to formally integrate AI-led embryology into routine clinical practice
  • Partnership with UK-headquartered IVF 2.0 to deploy SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) platforms
  • Pharmacy vertical operated through subsidiary remains smaller part of business
  • 15-bed Hospital facility at Janakpuri provides continuum from fertility treatment to delivery and post-natal care

Expansion Plans

  • 19 new IVF hubs planned under IPO use-of-proceeds
  • 3 hubs expected to be operational soon (Phase I)
  • Total of 10 hubs targeted for FY27
  • Additional 8 hubs planned for FY28 and 1 hub for FY29
  • Expansion focuses on Tier-II markets while reinforcing existing metro hubs with additional spokes

Management Commentary

Dr. Manika Khanna, Chairperson and Managing Director, stated that FY26 was a defining year as the company transitioned into a listed, institutional and scalable fertility platform. IVF Treatment remains the engine of the business, supported by 58%-plus clinical success rate in first attempt. The company is doubling down on technology with AI-led embryology expected to improve embryo selection consistency, reduce repeat cycles and strengthen patient confidence. With a debt-light balance sheet post-IPO and clearly funded expansion plan, Gaudium IVF believes it is well placed to compound growth responsibly.